GlobeNewswire by notified

Zoom Becomes the First Video Communications Client to Attain Common Criteria Certification

Share

Issued by the German Federal Office for Information Security, the Certification Reinforces Zoom’s Commitment to Security

SAN JOSE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM) today announced that Zoom Meeting Client version 5.6.6 has become the first video communications client to attain certification for Common Criteria Evaluation Assurance Level 2 (v3.1 rev. 5), issued by the German Federal Office for Information Security (BSI).

Common Criteria is an international standard for objectively evaluating that an IT product satisfies a defined set of security requirements. The evaluation involves analyzing a specific set of security targets, including guidance documentation, architectural design, life cycle aspects, testing and vulnerability assessment. The Zoom Meeting Client v5.6.6 has been evaluated by the BSI against the Common Criteria standard and found to exhibit a clear chain of evidence that the process of specification, implementation, and evaluation has been conducted in a rigorous and standard manner.

Mutually recognized in more than 25 countries including the UK, US, Canada, and Germany, Common Criteria is regarded as a leading benchmark for IT product security certification. A growing number of users expect IT vendors to produce trusted and reliable evidence for the cybersecurity capabilities of their products.

“This Common Criteria certification represents a major milestone for Zoom,” said Jason Lee, Chief Information Security Officer at Zoom. “We’re the first video communications client to receive this important certification, reinforcing our commitment to our customers. Security and privacy are the cornerstones of everything we do, and we are continually innovating secure solutions for all users of our platform.”

At present, the BSI has certified Zoom version 5.6.6 for Windows, macOS, iOS, and Android. While version 5.6.6 was the version of Zoom client available at the time of the certification, we always recommend customers utilize the newest version of the client to take advantage of Zoom's latest security updates and features.

“The Common Criteria certification is a global benchmark in cybersecurity,” said Sandro Amendola, Head of Standardization/Certification/Telecommunications Networks Security Department, BSI. “The Zoom client demonstrated a high security standard across its product, successfully completing one of the most demanding evaluation procedures a company can undertake.”

To learn more about Zoom’s Common Criteria certification, please visit the BSI website and the Zoom Trust Center.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ: ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Matt Nagel
press@zoom.us

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates16.8.2022 09:01:00 CEST | Press release

– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites – BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites. “This is

Cody Patrick Named OEM Direct Sales Manager for Nikkiso Clean Energy and Industrial Gases Group16.8.2022 09:01:00 CEST | Press release

TEMECULA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Cody Patrick has been named OEM Direct Sales Manager for Nikkiso ACD, a part of the Cryogenic Pumps unit of Nikkiso’s Clean Energy & Industrial Gases Group. Cody is a graduate of Texas A&M College of Engineering’s Industrial Distribution program. The combination of his education and experience with Cryogenic pumps for the industrial gases market, make him well suited to assist with growing the U.S. market. He will manage and develop business strategies and opportunities as well as assist with the development of training and educational programs for the Group’s clients. Cody will be based in Houston and report to Ian Guthrie, Business Line Manager for the Group’s Cryogenic Pumps unit. “Given Cody’s enthusiasm and understanding of the cryogenic pumps market we are excited t

Ahold Delhaize share buyback update16.8.2022 08:00:00 CEST | Press release

Zaandam, the Netherlands, August16, 2022 – Ahold Delhaize has repurchased 254,408 of its common shares in the period from August 8, 2022 up to and including August 12, 2022. The shares were repurchased at an average price of € 27.21 per share for a total consideration of € 6.9 million. These repurchases were made as part of the € 1 billion share buyback program announced on November 15, 2021. The total number of shares repurchased under this program to date is 20,621,088 common shares for a total consideration of € 561.6 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2022/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.

Sanionas Kv7-program för epilepsi avanceras till leadoptimering16.8.2022 08:00:00 CEST | Pressemelding

PRESSMEDDELANDE 16 augusti 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att bolaget har avancerat sitt lovande Kv7-program för epilepsi till fasen leadoptimering – den sista fasen av läkemedelsupptäckt innan en klinisk kandidat väljs ut. Thomas Feldthus, VD: ”Vi tror att vi har löst knäckfrågorna för att utveckla nästa generation av läkemedelskandidater av den här klassen, och vi ser en betydande potential att ta fram nya banbrytande epilepsibehandlingar. Finansiellt kan uppsidan vara avsevärd, att döma av vissa viktiga läkemedelsavtal som nyligen slutits på Kv7-området.” Miljontals människor runt om i världen påverkas i dag av epilepsi, en sjukdom som kännetecknas av återkommande krampanfall. Det medicinska behovet är stort, eftersom omkring 30 procent av patienterna inte svarar på behandling med konventionella läkemedel mot epilepsi. Läkemedel mot kramper kan desutom ha funktionshämmande biverkningar, som ofta måste minimeras genom no

Saniona progresses its Kv7 epilepsy program into Lead Optimization16.8.2022 08:00:00 CEST | Press release

PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”. Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these. Kv7 ion ch